0001821586-26-000007
SEC filingMoonLake reported a materially wider operating and net loss in Q1 2026 versus Q1 2025, reflecting intensified investment in SLK’s late-stage development and commercial preparation, consistent with management’s stated expectation of substantial ongoing losses through at least 2027.
Operating income for Q1 2026 was -$70.0 million, a 47.5% decline year-over-year from -$47.5 million in Q1 2025. This deterioration reflects the Company’s continued prioritization of clinical execution and commercial readiness for SLK, as affirmed in management commentary stating it expects to incur substantial expenses and operating losses for at least the next two years. The increase in losses is consistent with the strategic ramp-up of activities ahead of anticipated regulatory milestones, including Phase 3 readouts and the upcoming Biologics License Application filing.
Net income totaled -$69.7 million, down 74.5% from -$39.9 million in the prior-year quarter. Diluted EPS was $-0.98, compared to $-0.63 in Q1 2025 — a 55.6% decline. These results reflect the same underlying drivers as operating income, adjusted for non-operating items permitted under GAAP. The EPS change incorporates both the expanded net loss and the impact of share-based compensation awards granted under the 2022 Equity Incentive Plan, which management expects to continue granting to employees, directors, and non-employees.
Net cash used in operating activities was -$66.3 million, compared to -$38.1 million in Q1 2025. Free cash flow equaled -$66.3 million, as capital expenditures were $0 — a notable departure from the $35,000 incurred in Q1 2025. This absence of capital spending highlights the Company’s current focus on intangible investments: clinical trial execution, manufacturing scale-up, and pre-launch inventory accumulation. As noted in the business context, pre-launch production costs incurred prior to regulatory approval are expensed as R&D, not capitalized as inventory, reinforcing the link between cash outflows and accounting treatment.
Management explicitly states that pre-launch inventory buildup began in Q3 2025 and is expected to continue throughout 2026. This activity supports the commercial launch of SLK upon regulatory approval and is part of a broader pattern of intensified investment. The Company’s liquidity position remains governed by its cash burn trajectory and working capital changes, which the CODM evaluates alongside non-cash items to assess financial sustainability and cost management patterns. No updated liquidity assessment or forward-looking cash balance is provided in the authoritative packet, and therefore none is included here.